153 related articles for article (PubMed ID: 30683837)
1. Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model.
Vallapureddy RR; Mudireddy M; Penna D; Lasho TL; Finke CM; Hanson CA; Ketterling RP; Begna KH; Gangat N; Pardanani A; Tefferi A
Blood Cancer J; 2019 Jan; 9(2):12. PubMed ID: 30683837
[TBL] [Abstract][Full Text] [Related]
2. Mutations and prognosis in primary myelofibrosis.
Vannucchi AM; Lasho TL; Guglielmelli P; Biamonte F; Pardanani A; Pereira A; Finke C; Score J; Gangat N; Mannarelli C; Ketterling RP; Rotunno G; Knudson RA; Susini MC; Laborde RR; Spolverini A; Pancrazzi A; Pieri L; Manfredini R; Tagliafico E; Zini R; Jones A; Zoi K; Reiter A; Duncombe A; Pietra D; Rumi E; Cervantes F; Barosi G; Cazzola M; Cross NC; Tefferi A
Leukemia; 2013 Sep; 27(9):1861-9. PubMed ID: 23619563
[TBL] [Abstract][Full Text] [Related]
3. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
4. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
Guglielmelli P; Lasho TL; Rotunno G; Mudireddy M; Mannarelli C; Nicolosi M; Pacilli A; Pardanani A; Rumi E; Rosti V; Hanson CA; Mannelli F; Ketterling RP; Gangat N; Rambaldi A; Passamonti F; Barosi G; Barbui T; Cazzola M; Vannucchi AM; Tefferi A
J Clin Oncol; 2018 Feb; 36(4):310-318. PubMed ID: 29226763
[TBL] [Abstract][Full Text] [Related]
5. Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis.
Rago A; Latagliata R; Montanaro M; Montefusco E; Andriani A; Crescenzi SL; Mecarocci S; Spirito F; Spadea A; Recine U; Cicconi L; Avvisati G; Cedrone M; Breccia M; Porrini R; Villivà N; De Gregoris C; Alimena G; D'Arcangelo E; Guglielmelli P; Lo-Coco F; Vannucchi A; Cimino G
Leuk Res; 2015 Mar; 39(3):314-7. PubMed ID: 25636356
[TBL] [Abstract][Full Text] [Related]
6. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.
Tefferi A; Nicolosi M; Mudireddy M; Lasho TL; Gangat N; Begna KH; Hanson CA; Ketterling RP; Pardanani A
Leukemia; 2018 May; 32(5):1189-1199. PubMed ID: 29472717
[TBL] [Abstract][Full Text] [Related]
7. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.
Tefferi A; Guglielmelli P; Nicolosi M; Mannelli F; Mudireddy M; Bartalucci N; Finke CM; Lasho TL; Hanson CA; Ketterling RP; Begna KH; Naseema Gangat ; Pardanani A; Vannucchi AM
Leukemia; 2018 Jul; 32(7):1631-1642. PubMed ID: 29654267
[TBL] [Abstract][Full Text] [Related]
8. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
[TBL] [Abstract][Full Text] [Related]
9. Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia.
Quintás-Cardama A; Kantarjian H; Pierce S; Cortes J; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):315-318.e2. PubMed ID: 23391717
[TBL] [Abstract][Full Text] [Related]
10. Momelotinib therapy for myelofibrosis: a 7-year follow-up.
Tefferi A; Barraco D; Lasho TL; Shah S; Begna KH; Al-Kali A; Hogan WJ; Litzow MR; Hanson CA; Ketterling RP; Gangat N; Pardanani A
Blood Cancer J; 2018 Mar; 8(3):29. PubMed ID: 29515114
[TBL] [Abstract][Full Text] [Related]
11. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
[TBL] [Abstract][Full Text] [Related]
12. Prognosis of Primary Myelofibrosis in the Genomic Era.
Bose P; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S105-13. PubMed ID: 27521306
[TBL] [Abstract][Full Text] [Related]
13. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for leukemic transformation in patients with primary myelofibrosis.
Huang J; Li CY; Mesa RA; Wu W; Hanson CA; Pardanani A; Tefferi A
Cancer; 2008 Jun; 112(12):2726-32. PubMed ID: 18404742
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis.
Wang Z; Liu W; Wang M; Li Y; Wang X; Yang E; Ming J; Quan R; Hu X
Ann Hematol; 2021 Feb; 100(2):465-479. PubMed ID: 33386934
[TBL] [Abstract][Full Text] [Related]
16. Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis.
Tefferi A; Mudireddy M; Gangat N; Hanson CA; Ketterling RP; Pardanani A; Nagorney DM
Am J Hematol; 2017 Nov; 92(11):1187-1192. PubMed ID: 28782256
[TBL] [Abstract][Full Text] [Related]
17. One thousand patients with primary myelofibrosis: the mayo clinic experience.
Tefferi A; Lasho TL; Jimma T; Finke CM; Gangat N; Vaidya R; Begna KH; Al-Kali A; Ketterling RP; Hanson CA; Pardanani A
Mayo Clin Proc; 2012 Jan; 87(1):25-33. PubMed ID: 22212965
[TBL] [Abstract][Full Text] [Related]
18. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.
Senín A; Fernández-Rodríguez C; Bellosillo B; Camacho L; Longarón R; Angona A; Besses C; Álvarez-Larrán A
Ann Hematol; 2018 Mar; 97(3):443-451. PubMed ID: 29181548
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
[TBL] [Abstract][Full Text] [Related]
20. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
